ZURICH—Roche Holding AG has suspended late-stage trials of experimental diabetes drug taspoglutide due to side effects in another heavy blow to its medical pipeline, which is scheduled to be revamped after a series of development failures.
via online.wsj.com
No comments:
Post a Comment